Centre Hospitalier Universitaire De Toulouse

At Centre Hospitalier Universitaire De Toulouse, research in hematologic cancers focuses on aggressive and hard-to-treat diseases such as relapsed or refractory FLT3-mutated acute myeloid leukemia and Richter’s syndrome. These studies are designed to assess new treatment combinations and improve response rates in patients with limited options.

• Testing new combination therapies for acute myeloid leukemia
• Evaluating treatment effectiveness in Richter’s syndrome
• Exploring better ways to control advanced blood cancers

The work in this area aims to strengthen treatment outcomes while also examining how well patients tolerate these approaches in real-world clinical settings.

The Gérontopôle is actively involved in studies on Alzheimer’s disease, early Alzheimer’s disease, and mild cognitive impairment due to Alzheimer’s disease. This research is centered on improving symptom control, slowing cognitive decline, and finding more effective ways to detect and monitor disease progression.

• Assessing therapies for early Alzheimer’s disease
• Studying treatment options for mild cognitive impairment linked to Alzheimer’s disease
• Measuring changes in memory and daily functioning over time

Several trials at the site are focused on testing whether new neurology treatments can preserve cognition and function in older adults at different stages of disease.

Clinical research in respiratory medicine at this hospital includes studies in interstitial lung disease, with attention to progressive forms that involve inflammation. The main goal is to evaluate whether new or repurposed therapies can improve lung function and help slow disease worsening.

• Evaluating treatment benefit in interstitial lung disease
• Studying approaches for progressive lung disease with inflammatory features
• Measuring changes in breathing capacity and overall respiratory health

This area of research supports better management options for patients living with chronic and progressive lung conditions.